3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
5
Unknown
2
Terminated
2
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Hepatocellular
28
Carcinoma, Non-Small-Cell Lung
22
Lung Neoplasms
17
Cholangiocarcinoma
13
Biliary Tract Neoplasms
13
Small Cell Lung Carcinoma
12
Triple Negative Breast Neoplasms
8
Breast Neoplasms
8
Neoplasms
6
Neoplasm Metastasis
5
Liver Neoplasms
5
Urinary Bladder Neoplasms
4
Stomach Neoplasms
4
Pancreatic Neoplasms
4
Carcinoma
4
Non-Muscle Invasive Bladder Neoplasms
3
Gallbladder Neoplasms
3
Colorectal Neoplasms
3
Adenocarcinoma Of Esophagus
3
Pathologic Complete Response
2
Ovarian Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Bile Duct Neoplasms
2
Advanced Biliary Tract Cancer
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Vaccinia
1
SCLC, Limited Stage
1
Resectable Intrahepatic Cholangiocarcinoma
1
Interventions
pembrolizumab
21
enfortumab vedotin
13
Gemcitabine
12
Nivolumab
8
Cisplatin
8
Carboplatin
8
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Docetaxel
5
toripalimab
4
sacituzumab govitecan
4
Paclitaxel
4
Ipilimumab
4
atezolizumab
3
Mitomycin
3
Fluorouracil
3
disitamab vedotin
2
cabozantinib
2
avelumab
2
Radiosurgery
2
Platinum
2
Injections
2
Immunotherapy
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
Biopsy
2
zanidatamab
1
tremelimumab
1
tamibarotene
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Transitional Cell
×
durvalumab
×
Clear all
NCT03317158
2026-04-15
ADAPT-BLADDER
Hoosier Cancer Research Network
Phase 1/2
Recruiting
55 enrolled